We serve Chemical Name:5-Bromo-1H-pyrazolo[3,4-b]pyridin-3-amine CAS:405224-24-0 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
![5-Bromo-1H-pyrazolo[3,4-b]pyridin-3-amine](https://a.dearchem.com/CAS2/405224-24-0.png)
Chemical Name:5-Bromo-1H-pyrazolo[3,4-b]pyridin-3-amine
CAS.NO:405224-24-0
Synonyms:5-bromo-2H-pyrazolo[3,4-b]pyridin-3-amine;1H-Pyrazolo[3,4-b]pyridin-3-amine, 5-bromo-;5-Bromo-1H-pyrazolo[3,4-b]pyridin-3-ylamine;5-Bromo-1H-pyrazolo[3,4-b]pyridin-3-amine
Molecular Formula:C6H5BrN4
Molecular Weight:213.035
HS Code:2933990090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:429.1±40.0 °C at 760 mmHg
Density:2.0±0.1 g/cm3
Index of Refraction:1.824
PSA:67.59000
Exact Mass:211.969757
LogP:0.90
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:NONH for all modes of transpor
Packing Group:
Contact us for information like 5-bromo-2H-pyrazolo[3,4-b]pyridin-3-amine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,5-Bromo-1H-pyrazolo[3,4-b]pyridin-3-amine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,5-Bromo-1H-pyrazolo[3,4-b]pyridin-3-amine Use and application,5-Bromo-1H-pyrazolo[3,4-b]pyridin-3-ylamine technical grade,usp/ep/jp grade.
Related News: The growing use of biocatalysis in pharmaceutical chemistry promises to deliver on this need, while also offering substantial cost savings and faster time to market for urgently needed therapeutics. Carbonic acid, ethyl (1R)-1-phenylethyl ester manufacturers For seniors most in need of care, high-quality health care often is beyond reach. ChenMed brings concierge-style medicine — and better health outcomes — to the neediest populations. Physician-led and privately owned, ChenMed is a provider of choice for some 20 Medicare Advantage health insurance plans. 4-acetyl-3-diacetoxymethyl-2-phenyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-b]pyridine suppliers ICER’s researchers used a two-year treatment horizon in their model but noted that it’s unclear how long patients are supposed to remain on these treatments. The model may not fully capture the challenges the disease presents to patients, ICER acknowledged. 1,1′-dibromo-2,2′-dioxydiazenediyl-bis-p-menthan-8-ol vendor & factory.
